- Home
- ANIX vs MGNX Comparison
ANIX vs MGNX Comparison
Compare ANIX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- MGNX
- Stock Information
- Founded
- ANIX 1982
- MGNX 2000
- Country
- ANIX United States
- MGNX United States
- Employees
- ANIX N/A
- MGNX N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- MGNX Health Care
- Exchange
- ANIX Nasdaq
- MGNX Nasdaq
- Market Cap
- ANIX 108.9M
- MGNX 114.2M
- IPO Year
- ANIX 1987
- MGNX 2013
- Fundamental
- Price
- ANIX $3.18
- MGNX $1.48
- Analyst Decision
- ANIX Strong Buy
- MGNX Hold
- Analyst Count
- ANIX 3
- MGNX 9
- Target Price
- ANIX $9.00
- MGNX $5.33
- AVG Volume (30 Days)
- ANIX 104.7K
- MGNX 746.0K
- Earning Date
- ANIX 09-05-2025
- MGNX 08-05-2025
- Dividend Yield
- ANIX N/A
- MGNX N/A
- EPS Growth
- ANIX N/A
- MGNX N/A
- EPS
- ANIX N/A
- MGNX N/A
- Revenue
- ANIX N/A
- MGNX $154,050,000.00
- Revenue This Year
- ANIX N/A
- MGNX N/A
- Revenue Next Year
- ANIX N/A
- MGNX N/A
- P/E Ratio
- ANIX N/A
- MGNX N/A
- Revenue Growth
- ANIX N/A
- MGNX 255.31
- 52 Week Low
- ANIX $2.07
- MGNX $0.99
- 52 Week High
- ANIX $4.20
- MGNX $5.67
- Technical
- Relative Strength Index (RSI)
- ANIX 42.92
- MGNX 51.85
- Support Level
- ANIX $3.21
- MGNX $1.47
- Resistance Level
- ANIX $3.24
- MGNX $1.88
- Average True Range (ATR)
- ANIX 0.15
- MGNX 0.12
- MACD
- ANIX -0.02
- MGNX 0.01
- Stochastic Oscillator
- ANIX 6.98
- MGNX 26.83
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.